Addressing the Health Risks of Chemical Abortions and the Need for Medical Supervision
Prenatal Protections
FRG Resources
Chemical abortions, which use mifepristone and misoprostol, now account for over 50% of abortions in the U.S. Approved by the FDA in 2000, these drugs provide a non-surgical option but bring significant health risks, including hemorrhaging, infection, and incomplete abortion, which can require surgical intervention. Despite these risks, the FDA lifted the in-person dispensing requirements for mifepristone in 2021, making it easier for women to access these drugs remotely. While this change has increased accessibility, it also raises concerns, especially for women who may undergo these procedures without medical supervision or support.
First Rights Global advocates for policies that ensure safer use of chemical abortion drugs through medical oversight and informed consent measures. These measures would require that women receive comprehensive information on potential risks and complications. Research and policy examples from countries like Finland, which enforces medical supervision for chemical abortions, underscore the value of these protections in safeguarding women’s health.
Through resources and advocacy, First Rights Global aims to restore and prioritize policies that offer women essential medical support during chemical abortions, minimizing health risks and promoting informed, compassionate care.